A Financial Overview of Bausch Health in October

Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

Daniel Collins - Author
By

Aug. 18 2020, Updated 6:32 a.m. ET

uploads///Bausch

Revenue trends

Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.

Bausch Health (BHC) generated 78.0% of its net revenues from its Bausch + Lomb/International and Salix Pharmaceuticals divisions. These divisions reported combined 6.0% organic YoY growth. Wall Street analysts expect Bausch Health to generate revenues of $2.1 billion in the third quarter.

Article continues below advertisement
Article continues below advertisement

Among Bausch Health’s peers in the pharmaceuticals market, GlaxoSmithKline (GSK), Eli Lilly (LLY), and Teva Pharmaceutical (TEVA) generated second-quarter revenues of $9.9 billion, $6.3 billion, and $4.7 billion, respectively. The Invesco Dynamic Pharmaceuticals ETF (PJP) invests ~5.54% of its portfolio in Eli Lilly and ~2.88% in Bausch Health.

Expense trends

In the second quarter, Bausch Health (BHC) reported its cost of goods sold (excluding amortization and impairments of intangible assets) of $584.0 million. This figure reached $635.0 million in the second quarter of 2017. 

Bausch Health reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $94.0 million and $642.0 million, respectively, in the second quarter.

Bausch Health’s expenditures on the amortization of intangible assets grew from $623.0 million in the second quarter of 2017 to $741.0 million in the second quarter. Bausch Health reported expenditures on amortization of intangible assets of $1.5 billion in the first half of this year, compared to $1.3 billion in the first half of 2017.

Bausch Health’s net operating expenses totaled $6.6 billion in the first half of this year compared to $4.0 billion in the first half of 2017. Wall Street analysts expect Bausch Health to report SG&A and R&D expenses of $627.0 million and $94.0 million, respectively, in the third quarter.

Advertisement

Latest Eli Lilly and Co News and Updates

    Opt-out of personalized ads

    © Copyright 2024 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.